10.54

0.65% -0.065

Theravance Biopharma Inc (TBPH)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$10.61

Offen:

$10.49

24-Stunden-Volumen:

21,780

Relative Volume:

0.08

Marktkapitalisierung:

$538.51M

Einnahmen:

$62.02M

Nettoeinkommen (Verlust:

$-45.65M

KGV:

-11.46

EPS:

-0.92

Netto-Cashflow:

$-9.60M

1W Leistung:

-6.30%

1M Leistung:

+18.30%

6M Leistung:

+6.69%

1J Leistung:

+22.85%

1-Tages-Spanne:

$10.46

$10.63

1-Wochen-Bereich:

$10.46

$11.27

52-Wochen-Spanne:

$7.44

$11.82

Theravance Biopharma Inc Stock (TBPH) Company Profile

Firmenname

Theravance Biopharma Inc

Sektor

Healthcare (1174)

Branche

Biotechnology (661)

Telefon

650-808-6000

Adresse

UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-12

Neueste SEC-Einreichungen

TBPH's Discussions on Twitter

Vergleichen Sie TBPH mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TBPH Theravance Biopharma Inc	10.54	538.51M	62.02M	-45.65M	-9.60M	-0.92
VRTX Vertex Pharmaceuticals Inc	457.95	113.97B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	519.17	52.15B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	304.07	40.16B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	580.42	35.45B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	271.58	27.80B	3.81B	-644.79M	-669.77M	-6.24

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-08-06	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-04-12	Eingeleitet	BTIG Research	Buy
2024-01-08	Herabstufung	Evercore ISI	Outperform → In-line
2022-05-23	Eingeleitet	SVB Leerink	Outperform
2021-11-05	Hochstufung	JP Morgan	Underweight → Neutral
2021-09-15	Herabstufung	JP Morgan	Overweight → Underweight
2021-08-25	Herabstufung	Morgan Stanley	Overweight → Underweight
2021-08-24	Herabstufung	Cowen	Outperform → Market Perform
2020-10-14	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-07-07	Eingeleitet	JP Morgan	Overweight
2020-06-15	Eingeleitet	Morgan Stanley	Equal-Weight
2020-05-13	Eingeleitet	Cowen	Outperform
2020-01-08	Bestätigt	H.C. Wainwright	Buy
2019-11-06	Hochstufung	Robert W. Baird	Underperform → Neutral
2019-10-29	Eingeleitet	H.C. Wainwright	Buy
2018-03-29	Fortgesetzt	Piper Jaffray	Overweight
2017-08-17	Eingeleitet	Evercore ISI	Outperform
2017-06-16	Eingeleitet	Cantor Fitzgerald	Overweight
2017-05-11	Bestätigt	Needham	Buy
2016-12-21	Eingeleitet	Needham	Buy
2016-11-03	Eingeleitet	Piper Jaffray	Overweight
2016-10-12	Herabstufung	Robert W. Baird	Neutral → Underperform
2016-08-03	Herabstufung	BofA/Merrill	Neutral → Underperform
2016-06-20	Eingeleitet	Guggenheim	Buy
2016-06-20	Bestätigt	Leerink Partners	Outperform
2016-05-12	Eingeleitet	Leerink Partners	Outperform
2016-05-05	Herabstufung	BofA/Merrill	Buy → Neutral
2015-02-03	Hochstufung	Robert W. Baird	Underperform → Neutral

Alle ansehen

Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten

Jun 09, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 32,534 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Jun 09, 2025

Jun 06, 2025

Theravance and Mylan settle patent dispute with Eugia Pharma - MSN

Jun 06, 2025

theravance biopharma settles patent litigation with eugia pharma By Investing.com - Investing.com South Africa

Jun 06, 2025

Theravance and Viatris settle patent dispute with Eugia Pharma - Seeking Alpha

Jun 06, 2025

Theravance BiopharmaTheravance And Mylan Enter Settlement Agreement With EugiaSEC Filing - marketscreener.com

Jun 06, 2025

Theravance Biopharma Settles Patent Litigation with Eugia - TipRanks

Jun 06, 2025

theravance biopharma settles patent litigation with eugia pharma - Investing.com

Jun 06, 2025

Jun 04, 2025

(TBPH) Investment Analysis - news.stocktradersdaily.com

Jun 04, 2025

Theravance Biopharma Sells Remaining Trelegy Royalties to GSK for $225 Million - Global Legal Chronicle

Jun 04, 2025

Jun 03, 2025

TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises - sharewise

Jun 03, 2025

ProShare Advisors LLC Takes Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Jun 03, 2025

Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Bought by Millennium Management LLC - Defense World

Jun 03, 2025

Jun 02, 2025

Theravance Biopharma Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million - marketscreener.com

Jun 02, 2025

Theravance Biopharma Sells Trelegy Royalty Interest to GSK - TipRanks

Jun 02, 2025

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in T - GuruFocus

Jun 02, 2025

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million - Eagle-Tribune

Jun 02, 2025

Ameriprise Financial Inc. Cuts Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Jun 02, 2025

Jun 01, 2025

Nuveen Asset Management LLC Buys 48,635 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Jun 01, 2025

May 30, 2025

Deutsche Bank AG Purchases 15,608 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

May 30, 2025

Jane Street Group LLC Has $493,000 Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

May 30, 2025

May 29, 2025

Bank of America Corp DE Increases Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

May 29, 2025

May 28, 2025

Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders - Barchart.com

May 28, 2025

May 25, 2025

(TBPH) On The My Stocks Page - news.stocktradersdaily.com

May 25, 2025

May 23, 2025

Northern Trust Corp Has $3.67 Million Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

May 23, 2025

May 21, 2025

The past five years for Theravance Biopharma (NASDAQ:TBPH) investors has not been profitable - Yahoo Finance

May 21, 2025

May 20, 2025

Theravance Biopharma at H.C. Wainwright: Strategic Focus on YUPELRI and Ampreloxetine - Investing.com Canada

May 20, 2025

May 16, 2025

Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by StockNews.com - Defense World

May 16, 2025

May 15, 2025

When (TBPH) Moves Investors should Listen - news.stocktradersdaily.com

May 15, 2025

May 13, 2025

Theravance Biopharma to Participate in an Upcoming Investor Conf - GuruFocus

May 13, 2025

Theravance Biopharma to Participate in an Upcoming Investor Conference - Citizen Tribune

May 13, 2025

Price T Rowe Associates Inc. MD Buys 9,315 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

May 13, 2025

Dimensional Fund Advisors LP Acquires 95,304 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

May 13, 2025

May 12, 2025

We Think Some Shareholders May Hesitate To Increase Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation - simplywall.st

May 12, 2025

May 10, 2025

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025

May 09, 2025

Theravance Biopharma Announces Ampreloxetine Presentations at th - GuruFocus

May 09, 2025

Theravance Biopharma, Inc. Announces Ampreloxetine Presentations At the International MSA Congress - marketscreener.com

May 09, 2025

Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y - TradingView

May 09, 2025

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress | TBPH Stock News - GuruFocus

May 09, 2025

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress - Stock Titan

May 09, 2025

Theravance Biopharma: Promising Future with Strong Product Pipeline and Market Expansion - TipRanks

May 09, 2025